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Abstract 
BACKGROUND People with Huntington’s disease have been observed to have lower rates of cancers. 
OBJECTIVE To investigate the relationship between age of onset of HD, CAG repeat length and 
cancer diagnosis. METHODS Data were obtained from the European Huntington’s disease network 
REGISTRY study for 6540 subjects.  Population cancer incidence was ascertained from the 
GLOBOCAN database to obtain standardised incidence ratios of cancers in the REGISTRY subjects.   
RESULTS 173/6528 HD REGISTRY subjects had had a cancer diagnosis.  The age-standardised 
incidence rate of all cancers in the REGISTRY HD population was 0.26 (CI 0.22-0.30).  Individual 
cancers showed a lower age-standardised incidence rate compared with the control population with 
prostate and colorectal cancers showing the lowest rates.  There was no effect of CAG length on the 
likelihood of cancer, but a cancer diagnosis within the last year was associated with a greatly 
increased rate of HD onset (Hazard Ratio 18.94, p<0.001).  
CONCLUSIONS Cancer is less common than expected in the HD population, confirming previous 
reports.  However, this does not appear to be related to CAG length in HTT. A recent diagnosis of 
cancer increases the risk of HD onset at any age, likely due to increased investigation following a 
cancer diagnosis.   
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Introduction 
Huntington’s disease (HD) is an inherited neurodegeneration of mid-life onset.  It is caused by an 
expanded CAG repeat at the 5’ end of the HTT gene, which is translated to give a polyglutamine tract 
at the N-terminus of the encoded protein, huntingtin (HTT) (1).  It is characterised by a movement 
disorder, cognitive decline and variable psychiatric symptoms with early and continuing cell death in 
the striatum(1,2).  The disease is inexorably progressive and there is no treatment that can prevent 
the neurodegeneration(2). 
Studies in the systematic population registries of the Scandinavian countries show a reduction in the 
expected age-matched incidence of cancer in subjects with a diagnosis of HD and spinal and bulbar 
muscular atrophy (SBMA, Kennedy’s disease) another disease caused by an expanded CAG tract(3,4).  
Scandinavian countries have country-wide registers that record whole population health so mining 
these data can be potentially very productive.  Most countries do not have such comprehensive and 
well maintained registers and thus it is hard to replicate such studies.  However, the Oxford Record 
Linkage Group examined rates of cancers in an all-England population study, the English linked 
hospital episode statistics (LHES), 1999–2010, and showed a similar effect(5). They examined HD, 
SBMA, and a larger group of hereditary ataxias (HA), which include the CAG repeat expansion 
associated spino-cerebellar ataxias (SCAs).  The rate ratio cancer diagnosis in 4865 people with HD 
was 0.53, with no effect seen in subjects with a diagnosis of SBMA or HA.  More recently Coarelli et 
al. (6) questioned a cohort of HD and SCA patients directly about their experience of cancer and 
found standardised incidence ratios of 0.21 in HD and 0.23 in SCAs. 
A reduction in cancer incidence is seen in other neurodegenerative conditions.  A systematic 
examination of records from over 500,000 subjects in observational studies of CNS disorders showed 
a robust lower cancer co-occurrence in all neurodegenerations, with strikingly significantly lower 
rates in Alzheimer’s disease (ES 0.32)(7). Their HD data was derived from Ji and Sorensen(3,4). By 
contrast Freedman et al.(8) observed only a modestly reduced risk of Alzheimer’s disease in cancer 
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survivors in a prospective analysis of 1.16 million subjects in a Medicare population (HR = 0.87 (95% 
CI = 0.84-0.90). To follow up these studies we examined the incidence of cancers in the EHDN 
REGISTRY study directly.  We obtained the data from REGISTRY and the population rates from the 
Globocan study(9).  We also examined the effect of the CAG length and the age of onset of HD on 
cancer incidence. 
Materials and Methods 
Participants  
Data were provided from 6540 subjects participating in the REGISTRY study of the European 
Huntington's Disease Network (EHDN) prior to June 2013. 12 subjects originated in South East Asia 
and were excluded, giving 6528 subjects in the final study.  REGISTRY is a large, prospective study 
observing the natural course, clinical spectrum and management of HD in European countries.  More 
information on the REGISTRY study can be found at (http://www.euro-hd.net/html/REGISTRY).  All 
experiments were performed in accordance with the Declaration of Helsinki, full ethical approval for 
the REGISTRY study was obtained in each of the participating countries, and all participants gave 
written informed consent. The information includes demographics, HD related CAG repeat length, 
age at onset of HD, cancer and comorbidity, and medication data.  Whilst we obtained data on other 
aspects of medical history and on alcohol use, smoking, drug abuse and employment we did not use 
these in analysis as the numbers of cancer patients were relatively low and only 4 subjects were 
recorded as having a history of lung cancer, for instance. Thus further subdivision of the sample was 
not deemed useful.  Country of clinical site was obtained to adjust for country-specific cancer 
incidence with the UK, Spain, France, Germany, Italy, Poland given directly and a “Europe” category 
for all those from countries contributing relatively few subjects.  Incidences of cancer were identified 
by searching for "cancer", "carcinoma" and "malignant neoplasm" in the comorbidity data field and 
cross-checked using the ICD10 codes given: 171 patients were identified.  To provide some 
confirmation of the cancer diagnosis we looked for subjects taking medication specific for cancers 
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and 25/171 (14.6%) were confirmed by medication.  However, this search also identified two 
patients taking cancer-specific therapies who did not have cancer listed as a co-morbidity.  In the 
final sample we had 173 subjects with evidence for a diagnosis of cancer.   
 
Comparison of age-standardised cancer incidence 
In order to ascertain whether the number of cancer cases is more or less than might be expected we 
compared these data with age-adjusted cancer incidence from Europe available on the GLOBOCAN 
website (http://globocan.iarc.fr): the data used for the analysis were from 2012 (9) as the REGISTRY 
data were obtained in June 2013 and thus reflected data captured in the period 2012-13.   
The age-standardised incidence rate (SIR) was calculated (equation 1). Person-years were calculated 
from date of birth until date of diagnosis of cancer or the end of the study period (whichever came 
first), then the ratio of observed number of cases to expected number of cases was calculated but 
adjusted for age and sex.  This is important in this analysis as the REGISTRY cohort is substantially 
younger than those at highest risk for cancers in the European population and cancer incidence is 
age-related. 
��� =  ∑ �� ��=1∑ ������=1 =  ��∗ 
 
O = observed cancer cases in the study group (173), E* = sum of stratum-specific person years (nj) in 
subjects with HD x stratum-specific standard incidence rates (λj*) obtained from the GLOBOCAN 
reference group(9).  The age stratification is given in Table 1. The weighting was adjusted to reflect 
the proportions of different countries amongst the 6528 HD subjects. 
Relationship of cancer incidence to HTT CAG repeat length and age at onset of HD 
Equation 1 
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We analysed time from birth to HD onset using Cox proportional hazards models (10), adjusting for a 
time-varying covariate defined to be 0 until a person received a cancer diagnosis, and 1 thereafter. 
The effect of this is to compare, at every age, the rate of HD onset between those with, and without, 
a previous cancer diagnosis. This corrects for the fact that people with cancer are likely to be older 
(since they have lived long enough to develop cancer) than those without, and thus to have a later 
HD onset, since their HD incidence rates are being compared to people of the same age without a 
cancer diagnosis.  A Cox proportional hazard model was used to assess whether CAG repeat length 
was related to the age of cancer incidence, with adjustment for sex and stratification by country.  
We also assessed whether a cancer diagnosis influenced the age of onset of HD. 
To investigate the possibility that a cancer diagnosis may quickly bring about increased investigation 
of HD symptoms, and thus an apparent increase in HD incidence rate, we also included a time-
varying covariate that was only 1 during the year immediately following a cancer diagnosis, and 0 
elsewhere.  
Results 
There were 6540 patients identified from the EHDN REGISTRY study(11) with appropriate data: details 
are given in Table 1. Eight subjects were excluded as they were collected outside Europe (Singapore) 
and four had incomplete records. The 6528 subjects remaining were collected in European clinics, had 
a clinical diagnosis of HD and 173 (2.65%) of these patients also had information consistent with a 
cancer diagnosis. In the whole cohort 52.6% of subjects are female and 47.4% male. There is a higher 
proportion of females amongst those with a diagnosis of cancer than in those without (Table 1): this 
is attributable to the relative youth of our HD sample as the incidence of breast cancer is higher at 
relatively young ages compared with many other cancers. The sample size is too small to split by 
specific cancers to explore this further. The average age of the non-cancer HD subjects at the point of 
data collection (age at last visit) is over 10 years younger than in those with a cancer diagnosis and the 
mean CAG repeat length is longer in the non-cancer cohort than in the subjects with cancer (Table 1).  
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The distribution of the cancer diagnoses in the 173 subjects is given in Table 2.  The standardised 
incidence rate (SIR) of cancers in the HD population was calculated (Table 2) and for all cancers was 
0.26 (CI 0.22 – 0.30).  All cancers were observed at significantly lower levels than in the European 
population though there were differences in the rates between the types of cancer.  Uterine and 
skin cancers had age-standardised incidence rates closest to the European levels with colorectal, 
breast and prostate cancer all recorded at less than half the rates in the European population.   
Those with a cancer diagnosis have, on average, over 10 years later age of onset of HD than those 
without.  Testing whether this is significantly different, is, as noted above, complicated by the fact 
that cancer incidence rises as people age, and those with later ages of onset of HD will, on average, 
live longer and thus be more likely to develop a cancer(12). Modelling this using a cancer diagnosis 
at any time in the past as a time-dependent covariate in a Cox proportional hazards model(10) of 
time to HD onset, shows that those with a cancer diagnosis at any age are very slightly more likely to 
have HD onset than those without cancer at the same age (HR 1.2773; 95% CI 1.06 to 1.61, p < 
0.001).  A cancer diagnosis during the past year is strongly associated with an increased rate of HD 
onset (HR 18.95, 95% CI 13.01 to 23.20, p < 0.001). 
As we noted that the subjects with cancer diagnoses have shorter CAG repeat lengths than those 
without (Table 1), we investigated whether this is significantly associated with the likelihood of 
developing cancer.  Given that the CAG repeat showed the expected significant inverse correlation 
with age of HD onset (p < 2x10-16), the apparent association of cancer with CAG length could be a 
result of people with shorter CAG repeats  on average living longer (as age at death in HD is inversely 
correlated with expanded HTT allele CAG repeat length), and thus having a greater risk of developing 
cancer(12). To test whether this bias in lifetime length accounts for the apparent association 
between CAG length and cancer diagnosis we used a Cox proportional hazards model (10) with time 
from birth to cancer diagnosis as an outcome (death and HD diagnosis both as censoring) and CAG 
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length as a covariate. We also adjusted for age and sex and used different baseline hazards for the 
different countries.  There are no discernible effects of CAG repeat length on cancer incidence. 
Discussion 
The standardised incidence ratio for all cancers detected in the REGISTRY subjects is substantially 
lower than that in the non-HD population, as reported previously(3–6).  Cancer might be 
underdiagnosed in the HD population in later stages of the illness as potentially relevant signs or 
symptoms may not be noticed or acted upon, or may be masked by HD symptoms – cachexia for 
instance, common in cancers, is also common in late stage HD.  Our findings in the REGISTRY study 
show a lower rate of cancers than that reported in  previous studies of cancer in HD subjects in  
population cohorts (3–5) which could indicate under-ascertainment of cancer in our sample. 
However, the recent study examining French HD and SCA populations and asking directly about 
cancer show a similar SIR to that which we show in this study(6). However, it is also likely that having 
a diagnosis of HD, and therefore coming to clinical attention, makes diagnosis of any comorbidities 
more likely.  Turner et al.(5), studying hospital admission records in England, found that there was an 
increased rate of cancer diagnoses in the first year after admission for HD. The overall decrease in 
the rate of cancers that they observed among HD patients (rate ratio = 0.71)  was made more 
extreme if the first year was excluded (rate ratio = 0.53). This indicates that under-diagnosis is less 
likely in this population, rather than more likely: we showed a similar effect in the REGISTRY 
subjects.  The only cancer they found to be as common as in the general population was lung cancer, 
which Turner et al.(5) attributed to the higher rate of smoking in the HD subjects(13).  We had only 
four cases of lung cancer in our study, too few to study separately.  
The observation that two subjects were taking tamoxifen but had no recorded cancer diagnosis 
indicates that one of the reasons for the lower rate of all cancers observed here might well be poor 
recording of comorbidities in the REGISTRY database.  This could result from poor recall of the 
participant, lack of knowledge of their partners and carers in clinic or from subjects dropping out of 
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the study after a diagnosis of cancer due to treatment or other effects of the cancer itself and issues 
in the systematic collection of medical history in clinic. 
In an attempt to overcome the limitations of these data we investigated the effect of CAG repeat 
length on the time to a cancer diagnosis with the view that any correlation might implicate the CAG 
length at the HTT locus in promoting or delaying cancer. No such effect was observed. To further 
investigate any link between the two diseases we also examined whether having a cancer diagnosis 
was associated with age at onset of HD.  This is more difficult as there are competing risks: cancer 
risk is age-related, and a cancer diagnosis may influence time to death as well as time to HD onset, 
as may HTT CAG length.  However, we observe that a diagnosis of cancer at any time slightly 
increases the likelihood of HD onset: this marginal effect requires replication in further studies. In 
addition, the study of Turner et al.(5) found that cancer incidences were higher in the year around 
HD onset and we see a similar effect in the REGISTRY data.  This latter is likely to be an 
ascertainment bias: subjects receiving clinical attention are more likely to have any comorbid 
condition detected and therefore under-diagnosis of cancer is less likely in this population.   
What might underlie the later onset of cancer in HD subjects?  Defects in the DNA damage response 
(DDR) cause cancers (14) and the DDR has recently been implicated in altering the age at motor 
onset of HD and other repeat disorders (15,16).  The direction of this effect is unclear and alterations 
in the operation of the DDR have been shown to be both protective and deleterious in HD and other 
neurodegenerations. Mismatch repair and base-excision repair have both been implicated as 
promoting degeneration in the repeat disorders, possibly through somatic expansion of repeats 
(17,18).  Many other neurological diseases are caused by genetic defects in the DDR (19) but 
conversely, multiple protective effects of the DDR in neurodegenerations have also been observed 
(20–27).    
One consequence of the involvement of the DDR in modifying HD onset might be that although age 
at onset is later in subjects who have had a cancer diagnosis, if they have cancer in the presence of 
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lower DDR activity, then that cancer might be more aggressive with a faster course. HTT has been 
implicated in acceleration of breast cancer development and metastasis in mouse models of HD and 
to regulate cell division in mammary stem cells (28) . In subjects with breast cancer a reduction of 
ovarian cancer was shown in BRCA2 mutation carriers also carrying longer HTT CAGs(29), along with 
a paradoxical finding of increased metastasis and younger ages of cancer onset. Direct examination 
of metastatic breast cancer showed HTT mRNA downregulation in primary tumours and that the 
expression and localisation of the tight junction protein ZO1 was controlled by HTT(30). Lower 
expression of HTT was correlated with less HTT and ZO1 proteins at tight junctions, poorer 
differentiation of tumour cells and was predictive of worse cancer prognosis(31).  
It is not clear how the effect of increased CAG repeats, which translate to expanded polyglutamine 
tracts in the cognate proteins, could potentially mediate cancer risk but the underlying biology of HD 
offers clues.  Huntingtin (HTT) is expressed in all cells: cell death is promoted by mutant HTT (32–34) 
and non-mutant HTT is anti-apoptotic(35). HTT localises to spindle poles at mitosis and has a role in 
cell fate in neurons(36) that may extend to other cell types: therefore in neuronal cells it has been 
suggested that HTT regulates the balance between survival and death.  Most of the experimental 
work examining these functions has only looked at long (>40) CAGs compared with a single normal 
range CAG length thus our knowledge of the downstream effects of small differences in the CAG 
repeat length below 40 CAGs on HTT biology are limited.  If small modulations in CAG length in HTT 
and potentially other genes containing polymorphic CAG repeats impose a relatively small effect on 
cell fate decisions over a long period then they could well be one of the multiple factors that 
influence whether a cell divides or dies, contributing to the risk of uncontrolled cell division. The 
effect could in part be explained by the RNA generated from the expanded CAG repeat in HTT. 
sCAGs are small CAG repeat RNAs generated from the HTT gene (37) which are toxic to neurons (38) 
and may operate via an RNAi-based mechanism and downregulate trinucleotide repeat-containing 
survival genes, leading to tumour cell death (39). Similar findings in other neurodegenerative 
diseases(7) might implicate a broader biological relationship between cell survival and cell death in 
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the CNS, manifesting as neurodegeneration.  Thus determining the relationship between CAG length 
in HTT and other polymorphic CAG repeat loci could well reveal fundamental biological mechanisms 
underlying both cancer risk and neurodegeneration. 
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Table 1 Characteristics of those with and without a cancer diagnosis in the REGISTRY cohort 
Age  Non-cancer patients  Cancer patients  
 
n=6355 n= 173 
0 to 10  
11 to 20  
21 to 30  
31 to 40  
41 to 50  
51 to 60  
61 to 70  
71 to 80  
81 to 90  
91 to 100  
Average  
1 (0.02%)  
14 (0.2%)  
373 (5.9%)  
942 (14.8%)  
1588 (25.0%)  
1621 (25.5%)  
1218 (19.2%)  
502 (7.9%)  
92 (1.5%)  
4 (0.06%)  
52.1  
0 (0%)  
0 (0%)  
0 (0%)  
2 (1.2%)  
14 (8.1%)  
36 (20.8%)  
57 (33.0%)  
53 (30.6%)  
10 (5.8%)  
1 (0.6%)  
66.0  
M/F  3009/3346 (47.4%)  62/111 (64.2%)  
CAG Repeat Length  44.1 (±4.2) n=5029  42.1 (±2.3) n=173  
Age at onset HD  45.7 (±13.9) n=6354  58.0 (±10.7) n=154  
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Table 2 Standardised incidence rates of cancers in the REGISTRY population  
Cancer site SIR (95% Cl) # Cases 
Breast 0.37 (0.26-0.48)* 44 
Prostate 0.30 (0.17-0.43)* 20 
Skin 0.59 (0.33-0.85)* 20 
Uterus 0.66 (0.36-0.96)* 19 
Colorectal 0.26 (0.13-0.39)* 16 
Kidney 0.40 (0.12-0.68)* 8 
Other Sites 0.19 (0.13-0.24)* 46 
All 0.26 (0.22-0.30)* 173 
SIR = standardised incidence rate.  CI = confidence interval.  *significantly different from expected.  
Other sites include ovary (8), lung (4), bladder (4), brain (3), thyroid (3), liver/bile duct (3) and 
stomach (3). 
